Human cytochromes and some newer antidepressants: Kinetics, metabolism, and drug interactions

Journal of Clinical Psychopharmacology

Volumn 19, Issue 5 SUPPL. 1, 1999, Pages

  Greenblatt, David J ^a   Von Moltke, Lisa L ^a   Harmatz, Jerold S ^a   Shader, Richard I ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; CAFFEINE; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; CYTOCHROME P450; DESIPRAMINE; DIAZEPAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PHENYTOIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TACRINE; THEOPHYLLINE; VENLAFAXINE; WARFARIN;

DEPRESSION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INHIBITION; DRUG INTERACTION; DRUG METABOLISM; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 0032872510     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199910001-00003     Document Type: Review

References (184)

1. Wong DT, Bymaster FP, Engleman EA. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 1995;57:411-41.
2. Fjordside L, Jeppesen U, Eap CB, Powell K, Baumann P, Brøsen K. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics 1999;9: 55-60.
3. Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 1997;32[suppl 1]:22-30.
4. Fuller RW, Snoddy HD, Krushinski JH, Robertson DW. Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropharmacology 1992;31:997-1000.
5. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997;283:1305-22.
6. Sprouse J, Clarke T, Reynolds L, Heym J, Rollema H. Comparison of the effects of sertraline and its metabolite desmethylsertraline on blockade of central 5-HT reuptake in vivo. Neuropsychopharmacology 1996;14:225-31.
7. Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TCG, Zussman BD, Greb WH. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 1989; 80[suppl 350]:60-75.
8. DeVane CL, Gill HS. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design. J Clin Psychiatry 1997; 58[suppl 5]:7-14.
9. Sindrup SH, Brøsen K, Hansen MGJ, Aaes-Jørgensen T, Overø KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993;15:11-7.
10. Gram LF, Hansen MGJ, Sindrup SH, Brøsen K, Poulsen JH, Aaes-Jørgensen T, Overø KF. Citalopram interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit 1993; 15:18-24.
11. Hyttel J, Bøgesø KP, Perregarrd J, Sánchez C. The pharmacological effect of citalopram resides in the (S) - (+)-enantiomer. J Neural Transm Gen Sect 1992;88:157-60.
12. Bondolfi G, Chautems C, Rochat B, Bertschy G, Baumann P. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology (Berl) 1996;128:421-5.
13. Mayol RF, Cole CA, Luke GM, Colson KL, Kerns EH. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab Dispos 1994;22:304-11.
14. Greene DS, Barbhaiya RH. Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet 1997;33:260-75.
15. Marathe PH, Lee JS, Greene DS, Barbhaiya RH. Comparison of the steady-state pharmacokinetics of nefazodone after administration of 200 mg twice daily or 400 mg once daily in the morning or evening. Br J Clin Pharmacol 1996;41:21-7.
16. Howell SR, Husbands GEM, Scatina JA, Sisenwine SF. Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 1993;23:349-59.
17. Klamerus KJ, Parker VD, Rudolph RL, Derivan AT, Chiang ST. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy 1996;16:915-23.
18. Troy SM, Parker VD, Fruncillo RJ, Chiang ST. The pharmacokinetics of venlafaxine when given in a twice-daily regimen. J Clin Pharmacol 1995;35:404-9.
19. Kroemer HK, Eichelbaum M. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995;56:2285-98.
20. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphisms of S-mephenytoin hydroxylation. Pharmacol Ther 1989; 43:53-76.
21. Gonzalez FJ, Meyer UA. Molecular genetics of the debrisoquinsparteine polymorphism. Clin Pharmacol Ther 1991;50:233-8.
22. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Clin Pharmacokinet 1995;29:192-209.
23. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994;4: 285-99.
24. Gelboin HV. Cytochrome P450 and monoclonal antibodies. Pharmacol Rev 1993;45:413-53.
25. Crespi CL. Xenobiotic-metabolizing human cells as tools for pharmacological and texicological research. Adv Drug Res 1995;26: 179-235.
26. Crespi CL, Penman BW. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv Pharmacol 1997;43:171-88.
27. Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Drug interactions with newer antidepressants: role of human cytochromes P450. J Clin Psychiatry 1998;59[suppl 15]: 19-27.
28. Schmider J, Greenblatt DJ, Harmatz JS, Shader RI. Enzyme kinetic modeling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N-demethylation. Br J Clin Pharmacol 1996;41:593-604.
29. Newton DJ, Wang RW, Lu AYH. Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995;23: 154-8.
30. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994;268:1278-83.
31. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM, Harmatz JS, Shader RI. Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone, and venlafaxine. Psychopharmacology (Berl) 1996;128:398-407.
32. Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997;25:853-62.
33. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Wright CE, Harmatz JS, Shader RI. Human cytochromes mediating N-demethylation of fluoxetine in vitro. Psychopharmacology (Berl) 1997;132:402-7.
34. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach. J Pharm Sci 1998;87:845-53.
35. Hamelin BA, Trugeon J, Vallée F, Bélanger PM, Paquet F, LeBel M. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 1996;60: 512-21.
36. Stevens J, Wrighton S. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J Pharmacol Exp Ther 1993;266:964-91.
37. Kobayashi K, Ishizuka T, Shimada N, Yoshimura Y, Kamijima K, Chiba K. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos 1999;27:763-6.
38. Sindrup SH, Brøsen K, Gram L, Hallas J, Skjelbo E, Allen A, Allen GD, Cooper SM, Mellows G, Tasker TCG, Zussman BD. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:278-87.
39. Sindrup SH, Brøsen K, Gram L. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:288-95.
40. Bloomer JC, Woods FR, Haddock RE, Lennard MS, Tucker GT. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 1992; 33:521-3.
41. Spigset O, Granberg K, Hägg S, Norström Å, Dahlqvist R. Relationship between fluvoxamine pharmacokinetics and CYP2D6/ CYP2C19 phenotype polymorphisms. Eur J Clin Pharmacol 1997; 52:129-33.
42. Carrillo JA, Dahl ML. Svensson JO, Alm C, Rodríguez I, Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996;60:183-90.
43. Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 1995;58:399-403.
44. Spigset O, Granberg K, Hägg S, Söderström E, Dahlqvist R. Non-linear fluvoxamine disposition. Br J Clin Pharmacol 1998;45: 257-63.
45. Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T, Tani M, Yamamoto T, Ishizaki T, Kuroiwa Y. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 1997;280: 927-33.
46. Rochat B, Amey M, Gillet M, Meyer UA, Baumann P. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997;7:1-10.
47. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Duan SX, Fogelman SM, Harmatz JS, Shader RI. Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry 1999 (in press).
48. von Moltke LL, Greenblatt DJ, Granda BW, Grassi JM, Schmider J, Harmatz JS, Shader RI. Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berl) 1999;145:113-22.
49. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996;41:149-56.
50. Fogelman SM, Schmider J, Venkatakrishnan K, von Moltke LL, Harmatz JS, Shader RI, Greenblatt DJ. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 1999; 20:480-90.
51. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 1998;55:113-22.
52. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-58.
53. Tucker GT. The rational selection of drug interaction studies: implications of recent advances in drug metabolism. Int J Clin Pharmacol Ther Toxicol 1992;30:550-3.
54. Boobis AR. Prediction of inhibitory drug-drug interactions by studies in vitro. In: Pacifici GM, Fracchia GN, eds. Advances in drug metabolism in man. Luxembourg: The European Commission, 1995:513-39.
55. Leemann TD, Dayer P. Quantitative prediction of in vivo drug metabolism and interactions from in vitro data. In: Pacifici GM, Fracchia GN, eds. Advances in drug metabolism in man. Luxembourg: The European Commission, 1995:783-830.
56. Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, Sugiyama Y. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Ann Rev Pharmacol Toxicol 1998;38:461-99.
57. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998;50:387-412.
58. Segel IH. Enzyme kinetics. New York: John Wiley & Sons, 1975.
59. Obach RS. Nonspecific binding to microsomes. Drug Metab Dispos 1997;25:1359-69.
60. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
61. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15:125-31.
62. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-4.
63. Becquemont L, Le Bot MA, Riche C, Beaune P. Influence of fluvoxamine on tacrine metabolism in vitro: potential implication for the hepatotoxicity in vivo. Fundam Clin Pharmacol 1996;10:156-7.
64. Rasmussen BB, Nielsen TL, Brøsen K. Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. Pharmacol Toxicol 1998;83:240-5.
65. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Fogelman SM, Harmatz JS, Kramer SJ, Fabre LF, Shader RI. Gepirone and 1-(2-pyrimidinyl)-piperazine in vitro: human cytochromes mediating transformation and cytochrome inhibitory effects. Psychopharmacology (Berl) 1998;140:293-9.
66. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K. Dose-dependent inhibition of CYP1A2, CYP2C19, and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73-8.
67. Jeppesen U, Loft S, Poulsen HE, Brøsen K. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996;6:213-22.
68. Becquemont L, Ragueneau I, Le Bot MA, Riche C, Funck-Brentano C, Jaillon P. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther 1997;61:619-27.
69. Hiemke C, Weigmann H, Härtter S, Dahman N, Wetzel H, Müller H. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994;14:279-81.
70. Kashuba ADM, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML Jr, Kulawy RW, Beck DJ, Bertino JS Jr. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther 1998;64:257-68.
71. Ball SE, Ahern D, Scatina J, Kao J. Venlafaxine in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism: comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol 1997;43:619-26.
72. Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM. Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine. J Clin Pharmacol 1999;39:252-9.
73. Özdemir V, Naranjo CA, Shulman RW, Herrmann N, Sellers EM, Reed K, Kalow W. Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. J Clin Psychopharmacol 1998;18:198-207.
74. Özdemir V, Naranjo CA, Herrmann N, Shulman RW, Sellers EM, Reed K, Kalow W. The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline. J Clin Psychopharmacol 1998;18:55-61.
75. Schmider J, Greenblatt DJ, von Moltke LL, Karsov D, Shader RI. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin para-hydroxylation. Br J Clin Pharmacol 1997;44:495-8.
76. Hemeryck A, De Vriendt C, Belpaire FM. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes. Eur J Clin Pharmacol 1999;54:947-51.
77. Shader RI, Greenblatt DJ, von Moltke LL. Fluoxetine inhibition of phenytoin metabolism. J Clin Psychopharmacol 1994;14: 375-6.
78. Tremaine LM, Wilner KD, Preskorn SH. A study of the potential effect of sertraline on the pharmacokinetics of protein binding of tolbutamide. Clin Pharmacokinet 1997;32:31-6.
79. Priskorn M, Sidhu JS, Larsen F, Davis JD, Khan AZ, Rolan PE. Investigation of multiple-dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1997;44:199-202.
80. Marino MR, Langenbacher KM, Hammett JL, Nichola P, Uderman HD. The effect of nefazodone on the single-dose pharmacokinetics of phenytoin in healthy male subjects. J Clin Psychopharmacol 1997;17:27-33.
81. Rasmussen BB, Nielsen TL, Brøsen K. Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro. Eur J Clin Pharmacol 1998;54:735-40.
82. Jeppesen U, Rasmussen BB, Brøsen K. Fluvoxamine inhibits the CYP2C 19-calalyzed bioactivation of chloroguanide. Clin Pharmacol Ther 1997;62:279-86.
83. Xu ZH, Xie HG. Zhou HH. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br J Clin Pharmacol 1996;42:518-21.
84. Kobayashi K, Yamamoto T, Chiba K, Tani M, Ishizaki T, Kuroiwa Y. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 1995;40:481-5.
85. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53:401-9.
86. Belpaire FM, Wijnant P, Temmerman A, Rasmussen BB, Brøsen K. The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors. Eur J Clin Pharmacol 1998;54:261-4.
87. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994; 14:90-8.
88. Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J, Chung M. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997;17:284-91.
89. Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44:349-55.
90. Bergstrom R, Peyton A, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51:239-48.
91. Albers LJ, Reist C, Helmeste D, Vu R, Tang SW. Paroxetine shifts imipramine metabolism. Psychiatry Res 1996;59:189-96.
92. Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther 1997;62:145-56.
93. Sproule BA, Otton SV, Cheung SW, Zhong XH, Romach MK, Sellers EM. CYP2D6 inhibition in patients treated with sertraline. J Clin Psychopharmacol 1997;17:102-6.
94. Alfaro CL, Lam YW, Simpson J, Ereshefsky L. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol 1999; 19:155-63.
95. Solai LK, Mulsant BH, Pollock BG, Sweet RA, Rosen J, Yu K, Reynolds CF. Effect of sertraline on plasma nortriptyline levels in depressed elderly. J Clin Psychiatry 1997;58:440-3.
96. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. Br J Clin Pharmacol 1996;41:339-43.
97. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996;276:370-9.
98. Greene DS, Salazar DE, Pittman K, Barbhaiya RH. Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol 1995;15:399-408.
99. Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS. Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 1995;15:320-6.
100. Rickels K, Schweizer D, Case WG, DeMartinis N, Greenblatt DJ, Mandos LA, España FG. Nefazodone in major depression: adjunctive benzodiazepine therapy and tolerability. J Clin Psychopharmacol 1998;18:145-53.
101. Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies. J Clin Pharmacol 1996;36:792-8.
102. Schmider J, von Moltke LL, Shader RI, Harmatz JS, Greenblatt DJ. Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine. Drug Metab Rev 1999;31:545-60.
103. Wright CE, Lasher-Sisson TA, Steenwyk RC, Swanson CN. A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy 1992;12:103-6.
104. Piergies AA, Sweet J, Johnson M, Roth-Schechter BF, Allard S. The effect of co-administration of zolpidem with fluoxetine: pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 1996;34:178-83.
105. Gardner MJ, Baris BA, Wilner KD, Preskom SH. Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. Clin Pharmacokinet 1997; 32[suppl 1]:43-9.
106. Preskorn SH, Alderman J, Greenblatt DJ, Horst WD. Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo. Psychopharmacol Bull 1997;33:659-65.
107. Rapeport WG, Williams SA, Muirhead DC, Dewland PM, Tanner T, Wesnes K. Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry 1996;57[suppl 1]:20-3.
108. Perucca E, Gatti G, Cipolla G, Spina E, Barel S, Soback S, Gips M, Bialer M. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994;56:471-6.
109. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994;46:35-9.
110. Vella JP, Sayegh MH. Interactions between cyclosporine and newer antidepressant medications. Am J Kidney Dis 1998; 31:320-3.
111. von Moltke LL, Duan SX, Greenblatt DJ, Fogelman SM, Schmider J, Harmatz JS, Shader RI. Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms. Biol Psychiatry 1997;41:377-90.
112. Troy SM, Lucid I, Peirgeis AA, Parker VD, Klockowski PM, Chiang ST. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. J Clin Pharmacol 1995;35:410-9.
113. Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM. Effect of venlafaxine on the pharmacokinetics of alprazolam. Psychopharmacol Bull 1998;34:211-9.
114. Shader RI, von Moltke LL, Schmider J, Harmatz JS, Greenblatt DJ. The clinician and drug interactions - an update. J Clin Psychopharmacol 1996;16:197-201.
115. Schmider J, Greenblatt DJ, von Moltke LL, Shader RI. Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans. J Clin Psychopharmacol 1996;16:267-72.
116. Anderson IM, Tomenson BM. The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994;8:238-49.
117. Goodnick PJ, Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders: I. Basic pharmacology. J Psychopharmacol 1998;12[suppl B]:S5-S20.
118. Goodnick PJ, Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders: II. Efficacy and quality of life. J Psychopharmacol 1998;12[suppl B]:S21-S54.
119. Kasper S, Höflich G, Scholl HP, Möller HJ. Safety and antidepressant efficacy of selective serotonin re-uptake inhibitors. Hum Psychopharmacol 1994;9:1-12.
120. Richelson E. Pharmacology of antidepressants: characteristics of the ideal drug. Mayo Clin Proc 1994;69:1069-81.
121. Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A, Mason J. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. Br Med J 1993;306:683-7.
122. Dechant KL, Clissold SP. Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991;41:225-53.
123. Ellingrod V, Perry P. Nefazodone: a new antidepressant. Am J Health Syst Pharm 1995;52:799-812.
124. Gram LF. Fluoxetine. N Engl J Med 1994;331:1354-61.
125. Grimsley SR, Jann MW. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 1992; 11:930-57.
126. Holliday S, Benfield P. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs 1995;49:280-94.
127. Milne RJ, Goa KL. Citalopram: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991;41:450-77.
128. Murdoch D, McTavish D. Sertraline: a review of pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 1992;44: 604-24.
129. Nemeroff CB. The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor. Pharmacotherapy 1994;14:127-38.
130. Noble S, Benfield P. Citalopram: a review of its pharmacology, clinical efficacy and tolerability in the treatment of depression. CNS Drugs 1997;8:410-31.
131. Palmer KJ, Benfield P. Fluvoxamine: an overview of its pharmacological properties and review of its therapeutic potential in non-depressive disorders. CNS Drugs 1994;1:57-87.
132. Puzantian T. Mirtazapine: an antidepressant. Am J Health Syst Pharm 1998;55:44-9.
133. Rudorfer MV, Potter WZ. Antidepressants: a comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus the 'older' drugs. Drugs 1989;37:713-38.
134. Scott MA, Shelton PS, Gattis W. Therapeutic options for treating major depression, and the role of venlafaxine. Pharmacotherapy 1996;16:352-65.
135. Stimmel GL, Dopheide JA, Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997;17:10-21.
136. Tan JY, Levin GM. Citalopram in the treatment of depression and other potential uses in psychiatry. Pharmacotherapy 1999;19:675-89.
137. Ware MR. Fluvoxamine: a review of the controlled trials in depression. J Clin Psychiatry 1997;58[suppl 5]:15-23.
138. Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994;26:201-14.
139. Baker GB, Fang J, Sinha S, Coutts RT. Metabolic drug interactions with selective serotonin reuptake inhibitor (SSRI) antidepressants. Neurosci Biobehav Rev 1998;22:325-33.
140. Baumann P, Larsen F. The pharmacokinetics of citalopram. Rev Contemp Pharmacother 1995;6:287-95.
141. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996; 31:444-69.
142. Baumann P. Care and depression in the elderly: comparative pharmacokinetics of SSRIs. hit Clin Psychopharmacol 1998;13[suppl 5]:S35-S43.
143. Brøsen K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Invest 1993;71:1002-9.
144. Caccia S, Garattini S. Formation of active metabolites of psychotropic drugs: an updated review of their significance. Clin Pharmacokinet 1990;18:434-59.
145. Caccia S. Metabolism of the newer antidepressants: an overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 1998;34:281-302.
146. de Jonghe F, Swinkels J. Selective serotonin reuptake inhibitors: relevance of differences in their pharmacological and clinical profiles. CNS Drugs 1997;7:452-67.
147. Dostert P, Benedetti MS, Poggesi I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Psychopharmacol 1997;7[suppl 1]:S23-S35.
148. Goodnick P. Pharmacokinetics of second generation antidepressants: fluoxetine. Psychopharmacol Bull 1991;27:503-12.
149. Goodnick PJ. Pharmacokinetic optimisation of therapy with newer antidepressants. Clin Pharmacokinet 1994;27:307-30.
150. Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies. J Clin Pharmacol 1996;36:792-8.
151. Greene DS, Barbhaiya RH. Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet 1997;33:260-75.
152. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 1996;16:273-285, 345-55.
153. Ketter TA, Flockhart DA, Post RM, Denicoff KD, Pazzaglia PJ, Marangell LB, George MS, Callahan AM. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995;15:387-98.
154. Mitchell PB. Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Safety 1997;17:390-406.
155. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997;32[suppl 1]:1-21.
156. Preskorn SH. Debate resolved: there are differential effects of serotonin selective reuptake inhibitors on cytochrome P450 enzymes. J Psychopharmacol 1998;12[3 suppl B]:S89-S97.
157. Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 1997;72:835-47.
158. Spina E, Caputi AP. Pharmacogenetic aspects in the metabolism of psychotropic drugs: pharmacokinetic and clinical implications. Pharmacol Res 1994;29:121-37.
159. Spina E, Perucca E. Newer and older antidepressants: a comparative review of drug interactions. CNS Drugs 1994;2:479-97.
160. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. Clin Pharmacokinet 1996; 31:198-214.
161. Sproule BA, Naranjo CA, Bremner KE, Hassan PC. Selective serotonin reuptake inhibitors and CNS drug interactions: a critical review of the evidence. Clin Pharmacokinet 1997;33:454-71.
162. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993;24:203-20.
163. Clarke SE. In vitro assessment of human cytochrome P450. Xenobiotica 1998;28:1167-202.
164. Courts RT, Urichuk LJ. Polymorphic cytochromes P450 and drugs used in psychiatry. Cell Mol Neurobiol 1999;19:325-54.
165. Glue P, Clement RP. Cytochrome P450 enzymes and drug metabolism: basic concepts and methods of assessment. Cell Mol Neurobiol 1999;19:309-23.
166. Gonzalez FJ, Korzekwa KR. Cytochromes P450 expression systems. Ann Rev Pharmacol Toxicol 1995;35:369-90.
167. Gonzalez FJ. Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 1992;13:346-52.
168. Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Drug interactions with newer antidepressants: role of human cytochromes P450. J Clin Psychiatry 1998;59[suppl 15]:19-27.
169. Guengerich FP. Human cytochrome P-450 enzymes. Life Sci 1992;50: 1471-8.
170. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Ann Rev Pharmacol Toxicol 1999;39:1-7.
171. Ioannides C, ed. Cytochromes P450: metabolic and toxicological aspects. New York: CRC Press, 1996.
172. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998;35:361-90.
173. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45:525-38.
174. Nebert DW. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 1997;60:265-71.
175. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;6:1-42.
176. Park BK, Pirmohamed M, Kitteringham NR. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther 1995;68:385-424.
177. Parkinson A. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 1996;24:45-57.
178. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
179. Smith DA, Abel SM, Hyland R, Jones BC. Human cytochrome P450s: selectivity and measurement in vivo. Xenobiotica 1998;28:1095-128.
180. Smith G, Stubbins MJ, Harries LW, Wolf CR. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica 1998;28:1129-65.
181. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Ann Rev Pharmacol Toxicol 1998; 38:389-430.
182. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI. Cytochromes in psychopharmacology. J Clin Psychopharmacol 1994;14:1-4.
183. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-84.
184. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.